State of Tennessee Treasury Department Buys 167,806 Shares of Becton Dickinson and Co (NYSE:BDX)

State of Tennessee Treasury Department grew its holdings in Becton Dickinson and Co (NYSE:BDX) by 241.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 237,324 shares of the medical instruments supplier’s stock after buying an additional 167,806 shares during the quarter. State of Tennessee Treasury Department owned 0.09% of Becton Dickinson and worth $59,267,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc boosted its holdings in Becton Dickinson and by 1.3% in the third quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after acquiring an additional 283,433 shares during the last quarter. BlackRock Inc. increased its stake in shares of Becton Dickinson and by 1.9% in the fourth quarter. BlackRock Inc. now owns 19,384,283 shares of the medical instruments supplier’s stock worth $4,367,665,000 after acquiring an additional 355,223 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in shares of Becton Dickinson and by 22,485.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 6,545,502 shares during the last quarter. Ronna Sue Cohen increased its stake in shares of Becton Dickinson and by 24,129.0% in the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after acquiring an additional 5,710,365 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Becton Dickinson and by 10.4% in the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after acquiring an additional 416,459 shares during the last quarter. 84.54% of the stock is currently owned by institutional investors.

Becton Dickinson and stock opened at $252.01 on Friday. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.59. The firm has a market capitalization of $67.20 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 1.84 and a beta of 1.12. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $265.87. The stock’s fifty day simple moving average is $236.09.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.57 by $0.02. The company had revenue of $4.20 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The business’s quarterly revenue was down .6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.65 earnings per share. Equities research analysts forecast that Becton Dickinson and Co will post 11.69 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Friday, June 7th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date was Thursday, June 6th. Becton Dickinson and’s dividend payout ratio is 27.97%.

In other Becton Dickinson and news, EVP Simon D. Campion sold 2,903 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $236.94, for a total value of $687,836.82. Following the completion of the transaction, the executive vice president now directly owns 9,408 shares in the company, valued at approximately $2,229,131.52. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Samrat S. Khichi sold 16,085 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the completion of the transaction, the executive vice president now owns 12,608 shares of the company’s stock, valued at $2,958,845.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,154 shares of company stock valued at $4,955,775. 0.12% of the stock is owned by corporate insiders.

A number of equities analysts have recently weighed in on BDX shares. Raymond James dropped their price target on shares of Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, March 19th. Wells Fargo & Co dropped their price target on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating on the stock in a research note on Monday, May 13th. Zacks Investment Research downgraded shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. BMO Capital Markets dropped their price target on shares of Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating on the stock in a research note on Friday, May 10th. Finally, KeyCorp reissued an “overweight” rating and set a $262.00 target price (down from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. Six analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson and has an average rating of “Buy” and a consensus target price of $262.67.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: What is the return on assets (ROA) ratio?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.